Teva Pharmaceuticals is trading now 4.04% up at ILA 11080.00 after Moody’s Ratings upgraded its corporate credit rating to Baa3 from Ba1 with a stable outlook.
- The upgrade reflects continued execution of Teva’s Pivot to Growth strategy and improving credit quality; the company-specific catalyst is stronger than the broader healthcare sector’s positive tone.
- Trading is active during the August 11, 2026 regular session, with the stock above its August 10 close of ILA 10650.00, extending gains after its second-quarter revenue beat and raised brand outlook.